What is the recommended course of action for a patient currently taking Venlafaxine (Effexor) at a dose of 75 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Venlafaxine 75 mg: Dosing Recommendations

For a patient currently taking venlafaxine 75 mg daily, this represents the standard starting therapeutic dose, which can be maintained if effective, or increased by 75 mg increments at intervals of no less than 4 days up to 225 mg/day (or higher for severe depression), with the target therapeutic range being 150-225 mg/day. 1

Current Dose Assessment

  • 75 mg/day is the FDA-approved starting dose for venlafaxine immediate-release (administered in 2-3 divided doses with food) 1
  • For venlafaxine extended-release formulations, 75 mg once daily is within the therapeutic range, though many patients require higher doses for optimal response 2, 3
  • This dose has demonstrated efficacy: in breast cancer patients with hot flashes, 75 mg/day produced a 61% reduction in hot flash scores 4

Dose Titration Strategy

If clinical response is inadequate after 4-6 weeks:

  • Increase by 75 mg increments at intervals of no less than 4 days 1
  • Target the therapeutic range of 150-225 mg/day, which typically requires 2-4 weeks to reach 2
  • For moderately depressed outpatients, doses above 225 mg/day showed no additional benefit, but severely depressed inpatients responded to mean doses of 350 mg/day 1
  • Maximum dose is 375 mg/day in divided doses for severe or treatment-resistant depression 1, 5

Monitoring Requirements

Blood pressure monitoring is essential:

  • Cardiac conduction abnormalities and blood pressure increases occur particularly at higher doses 2
  • Approximately 10% of patients on average doses of 342 mg/day showed mildly raised blood pressure 6
  • Use with caution in patients with cardiac disease 2

Discontinuation Protocol

Never stop venlafaxine abruptly:

  • Venlafaxine must be tapered gradually to prevent discontinuation syndrome 4, 2, 1
  • This is particularly important with short-acting formulations like immediate-release venlafaxine 4
  • If intolerable symptoms occur during taper, resume the previous dose and decrease more gradually 1
  • Allow at least 7 days after stopping venlafaxine before starting an MAOI 1

Special Populations

Dose adjustments required for:

  • Hepatic impairment (mild-moderate): Reduce total daily dose by 50% 1
  • Renal impairment (GFR 10-70 mL/min): Reduce total daily dose by 25% 1
  • Hemodialysis patients: Reduce total daily dose by 50% 1
  • Elderly patients: No automatic dose adjustment needed, but exercise caution when increasing doses 1

Common Pitfalls

  • Inadequate trial duration: Allow 4-6 weeks at therapeutic doses before declaring treatment failure 2
  • Too-rapid titration: Increases should occur no more frequently than every 4 days to assess tolerability 1
  • Ignoring drug interactions: Venlafaxine has weak CYP2D6 inhibition, making it safer than paroxetine or fluoxetine when combined with tamoxifen 4
  • Abrupt discontinuation: This consistently causes withdrawal symptoms; always taper 4, 1

Side Effect Profile at 75 mg

  • Most common adverse events include nausea, dry mouth, dizziness, somnolence, insomnia, abnormal ejaculation, and sweating 3
  • Side effects are dose-related, with higher doses causing increased frequency and severity 4, 6
  • At 75 mg, tolerability is generally good, similar to SSRIs 3, 7

References

Guideline

Venlafaxine ER Dosage and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Tolerability of high-dose venlafaxine in depressed patients.

Journal of psychopharmacology (Oxford, England), 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.